Prostate Cancer Screening

  • Ian M. Thompson
  • Martin I. Resnick
  • Eric A. Klein

Part of the Current Clinical Urology book series (CCU)

Table of contents

  1. Front Matter
    Pages i-x
  2. Wael A. Sakr, Clara Ward
    Pages 1-23
  3. Peter C. Albertsen
    Pages 25-45
  4. Ruth Etzioni, David F. Penson
    Pages 47-62
  5. Faiyaaz M. Jhaveri, Michael K. Brawer, Eric A. Klein
    Pages 79-90
  6. Paul H. Lange
    Pages 97-104
  7. Aaron Sulman, Martin I. Resnick
    Pages 105-130
  8. David L. Shepherd
    Pages 131-145
  9. Chris Magee, Ian M. Thompson
    Pages 157-174
  10. Otis W. Brawley
    Pages 175-185
  11. Zinelabidine Abouelfadel, E. David Crawford
    Pages 239-254
  12. Fernand Labrie, Bernard Candas, Lionel Cusan, Jose-luis Gomez
    Pages 255-279
  13. Scott A. Optenberg, Atanacio C. Guillen, John P. Campbell, Ian M. Thompson
    Pages 281-289
  14. Fritz H. Schröder, Ingrid van der Cruijsen-Koeter, ERSPC Study Group
    Pages 291-310
  15. Back Matter
    Pages 311-318

About this book


With one man in six expected to develop prostate cancer during his lifetime, and with a variety of risk factors often complicating clinical assessment and treatment planning, the question of whether, and when, prostate screening should be performed has become the subject of heated debate. In Prostate Cancer Screening, world-class authorities from a variety of disciplines provide a comprehensive and balanced evaluation of the advantages and disadvantages of screening for prostate cancer. These experts critically review the various methods by which screening can be performed, evaluate the screening itself, compare prostate screening with screening at other organ sites, and explore the impact of screening on a multitude of other medical and social issues. In addition, the book includes a CD-ROM containing a sophisticated-but simple to use-decision-making program that allows the physician to gage a patient's risk of prostate cancer. Called CAPRI (Cancer of the Prostate Risk Index), this PC-based program uses the four most significant factors-a patient's PSA value, the results of the digital rectal exam, the patient's race, and the patient's age at biopsy-to predict the risk of prostate cancer. The patient's risk (with confidence intervals if desired) is displayed in an easily understood, visually provocative manner that allows both clinician and patient to more easily reach the decision as to whether biopsy is appropriate, as well as to educate the patient in general.
Comprehensive and balanced, Prostate Cancer Screening, presents a lively and rigorous evaluation of the science of prostate cancer screening, affording the health care provider with an informative discussion of its pros and cons, together with user-friendly computer program that analyzes an individual patient's risk of prostate cancer.


Biomarkers EPCA PSA PSA Screening Prostate Specific Antigen cancer prostate prostate cancer ultrasound

Editors and affiliations

  • Ian M. Thompson
    • 1
  • Martin I. Resnick
    • 2
  • Eric A. Klein
    • 3
  1. 1.Division of UrologyThe University of Texas Health Science Center at San AntonioSan AntonioUSA
  2. 2.University Hospitals of ClevelandCase Western Reserve UniversityClevelandUSA
  3. 3.Department of UrologyCleveland Clinic FoundationClevelandUSA

Bibliographic information